Cambridge spin-out secures £2.4 million for tumour treatments
21 Jun 2022
University of Cambridge spin-out Spirea Limited has secured £2.4 million in funding from British and American investors to increase drug development.
The funding will support its production of of antibody drug conjugate (ADC) therapeutics for meeting demand for solid tumour treatments.
ADCs apply cell killing and cancer targeting but a significant proportion of programmes fail their clinical development.
Spirea’s technology allows a greater amount of cell-killing cytotoxic drugs to combine with antibodies against cancer cells. This allows more tailored ADCs enabling greater efficacy and safety.
Spirea has previously received support from the likes of P Group, Cambridge Enterprise, Jonathan Milner and Syndicate Room.
Founder of Abcam and Meltwind Advisory CEO Milner commented on Spirea: “By developing a highly customisable platform where drug payloads and targets can be altered as needed, the company is revealing the true potential of ADCs as a cancer cell specific, highly effective therapeutic option for a wide range of cancers.”
